Kneu Health Celebrates Graduation from Texas Medical Center Innovation Accelerator Amid Growing U.S. Presence
Kneu Health, a platform specializing in precision neurology for conditions like Parkinson’s and dementia, is making significant strides in transforming the landscape of neurological care. The company recently celebrated its graduation from the Global Incubator program at the prestigious Texas Medical Center Innovation (TMCi). This achievement is especially notable as Kneu Health gears up to enhance its deployment efforts across leading healthcare systems in the United States, such as Cedars-Sinai and Mass General Brigham.
Founded with the vision of providing continuous neurological insight through smartphone technology, Kneu Health is tapping into over ten years of research spearheaded by the University of Oxford. Their smartphone-based platform enables patients to conduct brief daily assessments that effectively measure changes in movement, speech, and cognitive functioning. This data provides clinicians with structured clinical insights essential for detecting deterioration in a patient’s condition much earlier than traditional episodic care models would allow. Caroline Cake, the CEO and co-founder, pointed out that existing care models often rely on sporadic clinic visits, which yield limited snapshots of a patient’s overall health. By leveraging continuous monitoring, the team aims to support timely interventions that could significantly alter patient outcomes.
During their recent six-month clinical deployment with Cedars-Sinai’s Division of Movement Disorders, Kneu Health's innovative use of smartphone monitoring proved invaluable; clinicians noted that it facilitated earlier interventions in 79% of cases. In situations where they would have otherwise missed subtle yet crucial signs of progression, Kneu’s technology provided essential real-time updates that allowed for immediate attention and care adjustments.
Moreover, Kneu Health is on a trajectory of rapid expansion within the U.S. healthcare landscape. Following a successful clinical deployment with Cedars-Sinai, the company is now advancing its partnerships with notable health systems, including Mass General Brigham, renowned for its academic influence in healthcare. They recently secured $5.6 million in seed funding, co-led by Oxford Science Enterprises and Cedars-Sinai, which will facilitate further scale and integration of their platform across numerous health systems. In a remarkable development, Kneu has also received FDA clearance for its smartphone-based tremor measurement module, marking the first instance of a fully phone-operated system implemented for Parkinson's diagnosis. This innovation marks a monumental step in allowing more accessible and efficient patient monitoring.
Kneu Health is slated to take center stage at SXSW in Austin from March 12-16, where the company will showcase its impactful work and innovations to a broader audience. This milestone follows their triumph as the winner of the inaugural SXSW London Venture Spotlight, an accolade that includes a £100,000 prize recognizing the significance of Kneu’s contributions to smartphone-based monitoring in managing Parkinson's and dementia.
In summary, Kneu Health is not just participating in the evolution of neurology; they are leading it. With their continuous intelligence technology and commitment to enhancing patient care, the company is poised to reshape how neurological diseases are managed and monitored across the U.S. healthcare system. For more details regarding Kneu Health and its groundbreaking initiatives, visit their official website at https://kneu.com/en-us.
Founded with the vision of providing continuous neurological insight through smartphone technology, Kneu Health is tapping into over ten years of research spearheaded by the University of Oxford. Their smartphone-based platform enables patients to conduct brief daily assessments that effectively measure changes in movement, speech, and cognitive functioning. This data provides clinicians with structured clinical insights essential for detecting deterioration in a patient’s condition much earlier than traditional episodic care models would allow. Caroline Cake, the CEO and co-founder, pointed out that existing care models often rely on sporadic clinic visits, which yield limited snapshots of a patient’s overall health. By leveraging continuous monitoring, the team aims to support timely interventions that could significantly alter patient outcomes.
During their recent six-month clinical deployment with Cedars-Sinai’s Division of Movement Disorders, Kneu Health's innovative use of smartphone monitoring proved invaluable; clinicians noted that it facilitated earlier interventions in 79% of cases. In situations where they would have otherwise missed subtle yet crucial signs of progression, Kneu’s technology provided essential real-time updates that allowed for immediate attention and care adjustments.
Moreover, Kneu Health is on a trajectory of rapid expansion within the U.S. healthcare landscape. Following a successful clinical deployment with Cedars-Sinai, the company is now advancing its partnerships with notable health systems, including Mass General Brigham, renowned for its academic influence in healthcare. They recently secured $5.6 million in seed funding, co-led by Oxford Science Enterprises and Cedars-Sinai, which will facilitate further scale and integration of their platform across numerous health systems. In a remarkable development, Kneu has also received FDA clearance for its smartphone-based tremor measurement module, marking the first instance of a fully phone-operated system implemented for Parkinson's diagnosis. This innovation marks a monumental step in allowing more accessible and efficient patient monitoring.
Kneu Health is slated to take center stage at SXSW in Austin from March 12-16, where the company will showcase its impactful work and innovations to a broader audience. This milestone follows their triumph as the winner of the inaugural SXSW London Venture Spotlight, an accolade that includes a £100,000 prize recognizing the significance of Kneu’s contributions to smartphone-based monitoring in managing Parkinson's and dementia.
In summary, Kneu Health is not just participating in the evolution of neurology; they are leading it. With their continuous intelligence technology and commitment to enhancing patient care, the company is poised to reshape how neurological diseases are managed and monitored across the U.S. healthcare system. For more details regarding Kneu Health and its groundbreaking initiatives, visit their official website at https://kneu.com/en-us.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.